Viridian Therapeutics, Inc.
elegrobart
thyroid eye disease (TED)
Resolved
63days ago
Phase 3 readout · May 5, 2026
What's at stake
Phase 3 trial results for elegrobart in thyroid eye disease (TED) are due May 5, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the”